Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -0.64%1.18T | 11.51%4.91T | -0.91%1.18T | 15.35%1.27T | 13.91%1.26T | 19.42%1.19T | 12.39%4.4T | 13.60%1.19T | 10.05%1.1T | 24.97%1.11T |
Cost of revenue | -1.19%1.06T | 8.93%4.36T | -1.63%1.04T | 10.59%1.12T | 10.35%1.12T | 17.75%1.08T | 15.35%4T | 13.65%1.06T | 14.60%1.01T | 27.32%1.01T |
Gross profit | 4.59%119.68B | 37.19%550.66B | 4.81%138.7B | 68.19%153.34B | 51.99%144.19B | 37.83%114.43B | -10.50%401.39B | 13.14%132.33B | -23.65%91.17B | 4.37%94.87B |
Operating expense | 7.53%85.98B | 18.58%407.26B | -12.19%89.09B | 65.75%150.4B | 17.33%87.81B | 4.64%79.96B | 28.88%343.45B | 36.94%101.45B | 38.65%90.74B | 14.11%74.84B |
Selling and administrative expenses | 5.90%89.32B | 23.15%417.71B | 4.30%90.26B | 65.77%153.64B | 10.76%89.46B | 6.51%84.35B | 15.96%339.18B | 2.71%86.53B | 31.23%92.68B | 15.92%80.78B |
-General and administrative expense | 5.90%89.32B | 23.15%417.71B | 4.30%90.26B | 65.77%153.64B | 10.76%89.46B | 6.51%84.35B | 15.96%339.18B | 2.71%86.53B | 31.23%92.68B | 15.92%80.78B |
Other operating expenses | 42.74%3.4B | -40.61%18.34B | -54.10%9.77B | -47.62%2.45B | 130.31%3.74B | -27.76%2.38B | 212.14%30.88B | 408.97%21.28B | 303.54%4.68B | -37.65%1.62B |
Total other operating income | -0.40%6.75B | 8.17%28.79B | 71.93%10.93B | -14.05%5.69B | -28.65%5.39B | 11.47%6.77B | -25.87%26.61B | -55.67%6.36B | 4.47%6.62B | 12.78%7.56B |
Operating profit | -2.22%33.7B | 147.47%143.4B | 60.66%49.61B | 581.21%2.94B | 181.48%56.38B | 422.01%34.47B | -68.16%57.94B | -27.98%30.88B | -99.20%431M | -20.87%20.03B |
Net non-operating interest income (expenses) | -81.57%3.08B | 76.06%14.91B | 372.69%7.31B | 45.44%-6.06B | -258.68%-3.05B | -17.87%16.71B | -68.30%8.47B | -120.69%-2.68B | -212.31%-11.11B | 207.63%1.92B |
Non-operating interest income | -43.42%11.18B | 1.63%25.45B | 58.98%5.06B | -99.10%62M | -89.89%567M | -17.99%19.75B | -33.27%25.04B | -79.57%3.18B | -43.69%6.88B | 418.39%5.61B |
Non-operating interest expense | 165.86%8.1B | -36.40%10.54B | -138.30%-2.25B | -65.95%6.13B | -2.11%3.61B | -18.66%3.05B | 53.32%16.57B | 122.63%5.86B | 676.10%17.99B | 28.80%3.69B |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | -550.20%-14.81B | -214.91%-8.43B | -2,364.51%-12.57B | -76.27%435M | -72.26%418M | -26.91%3.29B | -34.90%7.33B | -120.25%-510M | 9.24%1.83B | -44.14%1.51B |
Special income (charges) | ||||||||||
Other non-operating income (expenses) | ||||||||||
Income before tax | -59.65%21.97B | 103.25%149.88B | 60.17%44.35B | 69.59%-2.69B | 129.17%53.76B | 73.20%54.46B | -66.48%73.74B | -52.55%27.69B | -113.50%-8.85B | -10.58%23.46B |
Income tax | -21.47%7.05B | 43.50%37.07B | 34.35%15.34B | -706.55%-6.53B | 131.22%19.27B | 30.37%8.98B | -58.98%25.83B | -20.14%11.42B | -103.77%-809M | 4.71%8.33B |
Net income | -67.19%14.92B | 135.47%112.81B | 78.29%29.01B | 147.69%3.83B | 128.05%34.49B | 85.21%45.48B | -69.49%47.91B | -63.06%16.27B | -118.24%-8.04B | -17.23%15.12B |
Net income continuous operations | -67.19%14.92B | 135.47%112.81B | 78.30%29.01B | 147.69%3.83B | 128.04%34.49B | 85.22%45.48B | -69.49%47.91B | -63.07%16.27B | -118.24%-8.04B | -17.23%15.12B |
Noncontrolling interests | -72.40%1.24B | 114.85%22B | 152.96%5.59B | 2,159.85%6.08B | 20.53%5.83B | 53.87%4.49B | -32.06%10.24B | 11.44%2.21B | -95.88%269M | 146.79%4.84B |
Net income attributable to the company | -66.62%13.68B | 141.08%90.81B | 66.56%23.41B | 72.98%-2.25B | 178.60%28.65B | 89.44%40.99B | -73.46%37.67B | -66.58%14.06B | -122.13%-8.31B | -36.94%10.29B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -66.62%13.68B | 141.08%90.81B | 66.56%23.41B | 72.98%-2.25B | 178.60%28.65B | 89.44%40.99B | -73.46%37.67B | -66.58%14.06B | -122.13%-8.31B | -36.94%10.29B |
Gross dividend payment | ||||||||||
Basic earnings per share | -66.62%16.92 | 141.06%112.31 | 66.55%28.9567 | 72.98%-2.7767 | 178.59%35.4367 | 89.44%50.6933 | -73.46%46.59 | -66.58%17.3867 | -122.13%-10.2767 | -36.95%12.72 |
Diluted earnings per share | -66.62%16.92 | 141.06%112.31 | 66.55%28.9567 | 72.98%-2.7767 | 178.59%35.4367 | 89.44%50.6933 | -73.46%46.59 | -66.58%17.3867 | -122.13%-10.2767 | -36.95%12.72 |
Dividend per share | 0 | 0.00%56.6667 | -10.00%30 | 0 | 14.29%26.6667 | 0 | 0.00%56.6667 | 0.00%33.3333 | 0 | 0.00%23.3333 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |